RISPERDAL CONSTA 37.5 MG Israel - engelsk - Ministry of Health

risperdal consta 37.5 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 37.5 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPERDAL CONSTA 37.5 MG Israel - engelsk - Ministry of Health

risperdal consta 37.5 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 37.5 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPERDAL CONSTA 50 MG Israel - engelsk - Ministry of Health

risperdal consta 50 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 50 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPERDAL CONSTA 50 MG Israel - engelsk - Ministry of Health

risperdal consta 50 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 50 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

Risperdal Consta New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal consta

janssen-cilag (new zealand) ltd - risperidone 25mg - suspension for injection - 25 mg/2ml - active: risperidone 25mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Risperdal Consta New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal consta

janssen-cilag (new zealand) ltd - risperidone 37.5mg - suspension for injection - 37.5 mg/2ml - active: risperidone 37.5mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Risperdal Consta New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal consta

janssen-cilag (new zealand) ltd - risperidone 50mg - suspension for injection - 50 mg/2ml - active: risperidone 50mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Risperdal New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal

janssen-cilag (new zealand) ltd - risperidone 0.5mg;  ;   - film coated tablet - 0.5 mg - active: risperidone 0.5mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Risperdal New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal

janssen-cilag (new zealand) ltd - risperidone 1mg;  ;   - film coated tablet - 1 mg - active: risperidone 1mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified water sodium laurilsulfate - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Risperdal New Zealand - engelsk - Medsafe (Medicines Safety Authority)

risperdal

janssen-cilag (new zealand) ltd - risperidone 2mg;  ;   - film coated tablet - 2 mg - active: risperidone 2mg     excipient: colloidal silicon dioxide hypromellose   lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate sunset yellow fcf titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.